MAZE logo

MAZE Maze Therapeutics Inc.

$26.43
$0.00
(0.00%)
Today
Closed $26.43
$0.00
(0.00%)
After Hours
37

Bearish Sentiment

How do you feel about MAZE?

Loading...

This is an ad slot. Start your free Edge trial and you won't see any ads for 30 days.

Ad free · Full sentiment data · Expanded watchers · Advanced search · No credit card required.

Advertisement|

Windy007
$MAZE 10:29 AM Truist analyst Danielle Brill views Vertex's (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL1-mediated kidney disease and estimates the data supports a potential addressable population of greater than 100,000 patients. The firm, which sees the data having "a significant positive readthrough" for Maze Therapeutics (MAZE), adds that while it remains too early to draw conclusions regarding relative efficacy, it believes the size of the opportunity is large enough to support blockbuster sales potential for MZE829 even if it ultimately demonstrates efficacy and safety comparable to inaxaplin. Truist has a Buy rating and $64 price target on Maze shares, which are up about 25% to $28.00 in morning trading.
onlyGreenPlz
Is $MAZE a buyout candidate? I know it’s too early to say but wondering what people thought.